Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics (BBNX) director reported open-market sales on 10/31/2025 under a Rule 10b5-1 plan adopted July 31, 2025. Two transactions were disclosed: 1,287 shares at a weighted average price of $26.8588 (range $26.27–$27.22) and 119 shares at a weighted average price of $27.4502 (range $27.32–$27.57).
Following these trades, the reporting person directly beneficially owns 9,841 shares. The filing notes full trade breakdowns by price increment are available upon request.
Beta Bionics (BBNX) reported Q3 results showing rapid top-line growth as it scales commercialization of the iLet Bionic Pancreas. Net sales were $27.3 million for the quarter, up from $16.7 million a year ago, driven by both device and recurring single‑use products across durable medical equipment and pharmacy channels. Gross profit reached $15.1 million, reflecting higher volumes.
Operating expenses rose with commercialization: research and development $8.2 million, sales and marketing $16.0 million, and general and administrative $7.9 million. The company posted a net loss of $14.2 million in Q3 and $59.7 million for the nine months. Loss per share was $0.33 on 43.6 million weighted‑average shares.
Liquidity strengthened post‑IPO. As of September 30, 2025, cash and cash equivalents were $38.5 million, short‑term investments $190.2 million, and long‑term investments $45.3 million. Total assets were $330.0 million and stockholders’ equity was $294.8 million. In January 2025, the company completed an IPO with approximately $190.4 million in net proceeds and a $15.6 million concurrent private placement; preferred stock and certain warrants converted to common. Shares outstanding were 44,024,631 as of October 24, 2025.
Beta Bionics, Inc. reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and is not deemed “filed” under the Exchange Act or incorporated by reference unless expressly stated otherwise.
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions dated 10/03/2025. He acquired 4,982 shares on that date through exercise of an employee stock option with an exercise price of $5.10, bringing his beneficial ownership to 49,023 shares immediately after the acquisition. On the same date he sold 3,828 shares at a weighted average price of $21.5172 and 1,154 shares at a weighted average price of $22.2778, executed pursuant to a Rule 10b5-1 plan adopted on 05/15/2025. After these transactions his reported beneficial ownership is 44,041 shares. The option shares vest in 48 equal monthly installments measured from 09/14/2023.
Beta Bionics (BBNX) reported an insider transaction by its Chief Financial Officer on 10/01/2025. The CFO exercised employee stock options for 15,018 shares at an exercise price of $5.10 per share, then sold 14,918 shares at a weighted average price of $20.76 and an additional 100 shares at $21.08, pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025.
Following these transactions, the officer beneficially owned 44,041 shares directly. The option exercise related to an award covering 15,018 underlying shares that vests in 48 equal monthly installments measured from September 14, 2023 and carries an expiration date of September 13, 2033. After the reported activity, 74,677 derivative securities (employee stock options) were beneficially owned.
Beta Bionics, Inc. Form 144 shows a proposed sale of 4,982 common shares through Merrill Lynch on 10/03/2025 with an aggregate market value of $108,076.24. The filing identifies prior insider sales by Stephen Feider in the past three months, including a 15,018-share trade on 10/01/2025 that generated $311,836.91 and other sales dated 09/08/2025, 09/05/2025, 08/22/2025, and 08/19/2025. The securities to be sold were acquired via stock options on 10/03/2025 and the filing indicates payment was made in cash on 10/01/2025. The seller represents there is no undisclosed material adverse information. The filing supplies transaction details but does not include the issuer's SEC file number, issuer address, or the filer CIK.
Insider sale notice for Beta Bionics, Inc. (BBNX): The filer reports a proposed sale of 15,018 common shares with an aggregate market value of $311,836.91 to be executed on 10/01/2025 on NASDAQ. The filing states the shares were acquired on 10/01/2025 through stock options granted by the issuer and paid for in cash.
The filing also discloses four recent transactions by the same seller totaling 20,000 shares sold between 08/19/2025 and 09/08/2025 with combined gross proceeds of $331,831.80. The filer certifies no undisclosed material adverse information and includes broker details for the planned sale.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclosed a shared, non‑sole beneficial ownership of 2,286,728 shares of Beta Bionics, Inc. common stock, representing 5.3% of the class. The filing on a Schedule 13G indicates the stake is reported under passive ownership rules, with no sole voting or dispositive power claimed and shared voting and dispositive power of 2,286,728 shares. Addresses and citizenships of the reporting persons are provided and a Joint Filing Agreement is attached.
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), exercised employee stock options and completed an offsetting sale on 09/08/2025. He exercised 9,900 options with an exercise/conversion price of $5.10 per share, resulting in acquisition of 9,900 shares underlying the option.
The same day Mr. Feider sold 9,900 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $21.12648 per share (range $21.00–$21.2933). After these reported transactions he beneficially owned 44,041 shares of common stock and reported 89,695 derivative securities beneficially owned.
Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported multiple option grants and open-market sales on 09/04/2025 and 09/05/2025. The filings show option awards exercisable at $5.10 and acquisitions of underlying common stock: 656, 4,093 and 11,411 option shares were added, increasing option holdings to 66,428; 33,136; and 21,725 respectively. Concurrently, 18,229 common shares were sold under a Rule 10b5-1 plan (6,818 at a weighted average $19.9736 and 11,411 at $20.564162). Following these transactions Hopman directly beneficially owned 31,215 common shares. Vesting schedules for the options are specified, with some vesting monthly from 09/14/2023 and others following a one-year cliff from 03/20/2023.